WillItSurvive
Medical technology and health companies · United States

JLK Inc

jlkgroup.com ↗

South Korean company selling FDA-cleared AI software that reads brain scans for stroke.

Losing its protection
Assessed 26 July 2026 · Evidence as of 26 July 2026
The structural protection is eroding.
On the recordSince 26 July 2026 · Checkable from Q1 2027 · Every call on the record Checkpoint: FY2026 annual results showing whether the KRW 51.8B backlog converts into recognized revenue
The call

JLK has the regulatory clearances and data that keep AI models and hardware giants out of its exact niche, but it is burning about four times its revenue while a better-funded Korean rival scales past it.

JLK Inc builds artificial intelligence software that helps doctors read MRI brain scans. It has real advantages: seven FDA approvals, 1.4 million labeled training images, and contracts with over 200 Korean hospitals. These regulatory and data advantages are hard to copy because the U.S. and Japanese governments require expensive approval before any competitor can sell this type of medical software. The main rival, a company called Lunit, is winning business with big hardware makers like GE and Philips, while JLK is burning through cash and losing roughly 4 dollars for every dollar it makes in revenue. The company's survival depends on whether its pipeline of pending orders actually converts into revenue and profit within the next two to four quarters, before shareholder dilution makes the company worth too little to stay independent.

Why
01
AI pressure: Generic frontier AI models attempting unvalidated stroke diagnostics. FDA and PMDA clearance rules block unvalidated AI models from diagnosing stroke, so generic models cannot ship here yet. Could AI do the core job? Unlikely.
02
Bigger players: Lunit. Lunit already partners with GE Healthcare and Philips, runs about 25x JLK's scale, and competes directly in Korean stroke AI. Could a giant copy it? Probably.
03
What protects it. Seven-plus FDA clearances, a 1.4M-image annotated stroke dataset, and live use in 200-plus Korean hospitals are hard for a generic model or a hardware vendor to replicate quickly.
What would change this call
JLK's 2026 annual revenue reaches ₩15-25B versus the claimed ₩51.8B backlog. Shows whether hospital contracts are converting to real sales or the backlog is stalling.
JLK reports FY2026 net loss narrowing below roughly ₩13B on higher revenue. Shows whether the 4x burn-to-revenue ratio is improving toward sustainability.
JLK issues new shares again in 2026, extending the ~16.7% YoY dilution trend. Shows whether shareholders keep absorbing losses via equity dilution.
Key numbers
  • FY2025 revenue ~KRW 3.34B, up about 134% YoY (2026-07-08)
  • 7+ FDA 510(k) clearances secured through March 2026 (2026-03-26)
  • Shares outstanding up ~16.7% YoY (2026-05-26)
Named risks
  • Net loss (~₩13.4B) running about 4x revenue (~₩3.3B) in FY2025. Severity: high
  • Ongoing shareholder dilution, shares outstanding up ~16.7% YoY as of May 2026. Severity: high
  • Out-scaled 10-25x by better funded domestic peers Lunit and VUNO. Severity: high
  • Order backlog (₩51.8B, vendor-claimed) may not convert into recognized revenue on schedule. Severity: medium
  • Small headcount (~70-80) limits capacity to scale commercial and regulatory operations. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Lunitlosing to₩83.1B 2025 revenue vs JLK's ₩3.3B, plus Microsoft Azure partnership from July 2, 2025
VUNOlosing to₩34.8B 2025 revenue, about 10x JLK's, with narrowing losses as of Feb 2026
Seers Technologylosing toFirst Korean listed medical AI firm to reach full-year operating profit in 2025
GE HealthCare, Philips, FujifilmcontestingEmbedding AI directly into imaging hardware and partnering with Lunit, not JLK, as of Dec 2025
Questions people ask
Is JLK Inc profitable in 2026?
No. JLK posted a net loss of about ₩13.4 billion in FY2025 against revenue of only ₩3.34 to 3.36 billion, a roughly 4x burn to revenue ratio, per Pitchbook data as of July 8, 2026. No profitability has been reported yet despite a 134 percent YoY revenue jump.
Who is JLK Inc's biggest competitor?
Lunit, a fellow Korean KOSDAQ-listed medical AI firm, is JLK's biggest rival, reporting ₩83.1 billion in 2025 revenue, about 25 times JLK's ₩3.3 billion, plus a Microsoft Azure partnership announced July 2, 2025 and over 10,000 institutional users.
Could AI replace JLK Inc's diagnostic products?
Unlikely soon. JLK's stroke and imaging AI tools require FDA 510(k) or PMDA clearance, a regulated liability-bound process that blocks unvalidated frontier models from shipping competing diagnostics, giving JLK's 7-plus FDA clearances as of March 2026 real protective cover.
Who owns JLK Inc and is it publicly traded?
JLK Inc is an independently owned, publicly traded company listed on KOSDAQ under ticker 322510, having IPO'd December 11, 2019 as the first medical-AI company on that exchange. Founder Won-Tae Kim sold about 330,707 shares, worth roughly $3.9 million, in August 2024.
How much has JLK Inc's revenue grown recently?
JLK's FY2025 revenue rose to roughly ₩3.34 to 3.36 billion, up about 134 to 135 percent year over year, following a 42.65 percent decline in FY2024 to ₩1.43 billion, per stockanalysis.com data published July 8, 2026.
Does JLK Inc have FDA approval for its AI products?
Yes. As of March 26, 2026, JLK held 7 or more FDA 510(k) clearances covering stroke, hemorrhage, and perfusion imaging tools including JLK-NCCT, JLK-ICH, JLK-SDH, JLK-CTP, JLK-LVO, JLK-PROSTATE, and JLK-AILink, alongside parallel Japan PMDA approvals.
Timeline
  • 2026-06-17Named lead institution for ₩2.8B government stroke AI R&D program through Dec 2028
  • 2026-06-16Reports ₩51.8B order backlog and rising evaluation center utilization amid stock rally
  • 2026-03-26Secures FDA 510(k) clearance for JLK-NCCT non-contrast CT stroke detection tool
  • 2025-07-16Reports over 200 Korean hospitals using its solutions and PMDA approvals in Japan
  • 2025-03-05Wins 7th FDA 510(k) clearance, for JLK-SDH
  • 2025-02-26Secures FDA clearance for JLK-AILink integrated imaging platform
  • 2025-01-06Wins FDA approval for JLK-ICH intracranial hemorrhage detection
  • 2024-10-17Secures FDA 510(k) clearance for JLK-CTP stroke solution
  • 2024-08-01Founder Won-Tae Kim sells about 330,707 shares worth roughly $3.9M
  • 2019-12-11JLK IPOs on KOSDAQ, first medical-AI company listed there
Revision history
26 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources